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Abstract: The goal of the AntiBotABE Program was the development of recombinant antibodies that
neutralize botulinum neurotoxins (BoNT) A, B and E. These serotypes are lethal and responsible for
most human botulinum cases. To improve therapeutic efficacy, the heavy and light chains (HC and
LC) of the three BoNT serotypes were targeted to achieve a synergistic effect (oligoclonal antibodies).
For antibody isolation, macaques were immunized with the recombinant and non-toxic BoNT/A, B or
E, HC or LC, followed by the generation of immune phage-display libraries. Antibodies were selected
from these libraries against the holotoxin and further analyzed in in vitro and ex vivo assays. For each
library, the best ex vivo neutralizing antibody fragments were germline-humanized and expressed
as immunoglobulin G (IgGs). The IgGs were tested in vivo, in a standardized model of protection,
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and challenged with toxins obtained from collections of Clostridium strains. Protective antibody
combinations against BoNT/A and BoNT/B were evidenced and for BoNT/E, the anti-LC antibody
alone was found highly protective. The combination of these five antibodies as an oligoclonal
antibody cocktail can be clinically and regulatorily developed while their high “humanness” predicts
a high tolerance in humans.
Keywords: AntiBotABE; botulinum; toxin; phage-display; IgG; neutralization; botulism; biodefense;
recombinant; oligoclonal antibodies
1. Introduction
The aim of the AntiBotABE Program was to develop recombinant antibodies that neutralize
botulinum neurotoxins (BoNT) A, B and E, responsible for most human botulism cases. The heavy
and light chains (HC and LC) of the three BoNT serotypes were targeted to achieve a synergistic effect
(oligoclonal antibodies). Our strategy used macaque immune libraries to develop neutralizing/protective
antibodies and was successfully applied in former projects against ricin [1], the lethal toxin of anthrax [2,3],
Venezualan equine encephalits virus [4], Western equine encephelatis virus [5] and Marburg virus [6].
1.1. Background
BoNTs are among the most toxic known substances—whether of biological or chemical origin,
they are part of the “dirty dozen” agents listed as possible bioweapons. The Gram-positive, anaerobic
spore-forming bacterium Clostridium botulinum and other Clostridium spp. produce seven serotypes
(A–G) of botulinum neurotoxin (BoNT), among which only four serotypes cause human botulism.
In humans, botulism is characterized by a progressive and flaccid muscle paralysis that occurs naturally
following food poisoning or colonization of the gastrointestinal tract by BoNT-producing Clostridia [7,8].
Human botulism is generally caused by BoNT/A, B and E while BoNT/F is involved in only 1%
of food poisoning-related cases of botulism [9–11]. The BoNT/H has recently been presented as
a new serotype of botulinum toxin in 2014 [12,13]. However, further analyses indicate that this is
a hybrid-like BoNT, containing regions of BoNT/A1 and BoNT/F5, which is fully neutralized by
serotype A antitoxin [14]. The more recently discovered BoNT/X adds to the BoNT diversity as a
recognized new serotype as well as the “BoNT-like” toxin from Weissella, a homolog of BoNTs that
also cleaves VAMP2 [15,16].
Botulinum neurotoxin A (BoNT/A) is the deadliest biological substance currently known, with
lethal dose values (LD50: toxin dose that kills half of the animal population) of 1 ng/kg by the intravenous
and subcutaneous routes and 3 ng/kg by the pulmonary route. These values were extrapolated from
experiments with non-human primates. BoNT/E-related intoxications are scarcer than those related to
BoNT/A and BoNT/B, but the median LD50 of BoNT/E is estimated to be as low as that of BoNT/A,
equal to 1.1 ng/kg in mice and monkeys by intraperitoneal route [17]. Like a few other BoNT serotypes,
BoNT/E is secreted as a unique inactive chain by group II C. botulinum strains that requires activation
by host proteases. This process—called nicking—is associated with a 100-fold increase in toxicity [18].
Due to its extreme toxicity, ease of production and lack of antidotes, BoNT is classified as a category A
biothreat agent by the United States Centres for Disease Control and Prevention [19,20]. The Soviet Union
and Iraq have been suspected of weaponizing BoNTs as reported by U.N. Officers (but rejected by several
countries). A former scientist in the Russian bioweapon program reported that Soviets had attempted
splicing the botulinum gene into other bacteria [21,22]. Furthermore, the risk of contamination of
the food chain by BoNTs has been highlighted in several potential scenarios [23]. Besides potential
bioterrorist attacks, naturally-occurring food intoxications—rare but often severe—are still encountered
including infant botulism cases due to intestinal colonisation by Clostridium spores and intoxications
due to the cosmetic use of poor quality BoNT have also been reported.
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1.2. Botulinum Neurotoxins (BoNTs)
Botulinum neurotoxins (BoNTs) cause flaccid paralysis by inducing a blockade at voluntary
motor and autonomic cholinergic junctions that, if not treated, causes a deadly paralytic disease
called botulism. BoNTs are type A-B heteromeric molecules composed of a 100 kDa HC and a
50 kDa LC. BoNT is a modular nanomachine composed of a N-terminal Zn2+-metalloprotease, which
cleaves the SNAREs (Soluble N-éthylmaleimide-sensitive-factor Attachment Protein Receptors); a
central helical protein-conducting channel, which chaperones the protease across endosomes; and a
C-terminal receptor binding module, consisting of two subdomains that determine target specificity
by binding to a ganglioside and a protein receptor on the cell surface, triggering endocytosis [24,25].
The HC binds to polysialo-gangliosides and, depending of the BoNT serotype, to different receptors
on the surface of the motoneurons [26,27], triggering the internalization by dual-receptor-mediated
endocytosis with translocation of the LC into the cytosol. The properties and mode of actions of
BoNTs have paved the way for neuronal transport elucidation and protein-protein interaction while
stimulating basic mechanistic studies [28]. Botulism occurs when BoNT has reached the peripheral
nerve endings via the bloodstream—commonly due to food intoxication—but mechanisms behind the
absorption of BoNT through mucosal membranes are not well understood. The BoNT as a complex
comprises hemagglutinin proteins (HA). Epithelial cell line based assays indicate that HA proteins
are pathogenic factors that disrupt the paracellular barrier of the intestinal epithelium by directly
binding to E-cadherin and inhibiting E-cadherin-mediated cell-to-cell adhesion [29–32]. In addition,
in a mouse ligated intestinal loop model, BoNT translocation through the intestinal barrier has been
shown to occur via an endocytosis-dependent mechanism while BoNT further targeted neuronal cells
and neuronal extensions in the intestinal submucosa [33,34]. However, BoNT serotypes E and F lack
HA encoding genes and are produced without HA proteins, yet they cause botulism.
Despite extensive research, no small synthetic molecule has been approved for therapeutic
use against botulism and Europe now relies on a heptavalent equine anti-toxin serum (HBAT, by
Cangene Corporation, Winnipeg, MB, Canada, now part of Emergent Biosolutions), of which there
are limited stockpiles and which still presents the risk of inducing adverse effects. Development of
small inhibitors acting independently of BoNT immunological properties and targeting a common
step of the intoxication process is encouraged, yet no specific inhibitor has been developed to date [35].
In the USA, two treatments based on the passive administration of antibodies are available. The
first one—BabyBIG®—is supplied by the California Department of Public Health and is composed of
human immunoglobulins obtained from pooled-plasma from subjects immunized with a pentavalent
vaccine composed of BoNT/A, B, C, D and E toxoids. The second antidote consists of a preparation
composed of antitoxins obtained from horses immunized with the heptavalent vaccine (HBAT) [36].
Two major limitations are that the stock of BabyBIG® is limited and that the equine serum (HBAT)
may cause serious adverse effects such as serum sickness [37,38]. The HBAT contains fragments of IgG
targeted against seven BoNT types derived from equine plasma consisting of <2% intact IgG and≥90%
Fab or F(ab’)2 immunoglobulin fragments to reduce the hypersensitivity reaction [39]. Nonetheless,
the Fab and F(ab’)2 fraction are eliminated from blood circulation more rapidly than intact IgGs,
which makes HBAT plasma’s half-life shorter and may lead to serious consequences when botulism or
exposure to BoNT is prolonged [40,41]. This occurred when a patient with BoNT/F intestinal botulism
showed improvement after HBAT administration but bilateral descending flaccid paralysis recurred
when Fab/F(ab’)2 IgG fragments were cleared from the circulation and BoNT/F rebounded [40].
BoNT is a double-edged sword with both toxic effects and therapeutic benefits, excluding
vaccination as a widely applied preventative measure. Vaccines against botulism have been developed
but vaccination is rarely used as its effectiveness has not been fully evaluated and its safety is
questionable [41]. Thus, vaccination is only used for individuals with a high risk of exposure such as
health care providers, researchers, first responders, and military personnel [42]. Meanwhile, BoNTs
have been introduced as a safe and effective treatment for a wide range of disorders associated with
involuntary muscle contractions and spasm disorders, and these ever-increasing medical indications
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prevent large scale vaccination against botulism [43]. Minute doses of this deadly poison are used
therapeutically to locally paralyse muscles for clinical or cosmetic benefit. Initially used to treat
strabismus, botulinum toxin has now more than a hundred possible medical applications including
movement disorders, hemifacial spasm, essential tremor, tics, writer’s cramp, cervical dystonia,
cerebral palsy and vascular cerebral stroke. Botulinum toxin has recently been approved for chronic
pain, migraine headache, overactive bladder and inflammation [44,45].
The current situation therefore supports the need for new human-like antibody preparations that
are highly-effective and better tolerated than equine antibodies but because BoNT serotypes differ
by up to 70% in their amino acid sequence, it is necessary to neutralize each serotype with specific
antibodies [46]. More importantly, for human application, optimal tolerance of antibodies is of major
therapeutic relevance. However, it is not always possible to immunize human volunteers with the
antigen of interest, particularly in the case of biological warfare agents. Human volunteers may be
replaced by non-human primates for the construction of immune libraries. It was demonstrated that
macaque antibodies are close to their human counterparts, which might support a good tolerance in
therapy [47,48]. The AntiBotABE project focused on the development of recombinant antibodies to
neutralize the most lethal types of BoNTs: A (subtypes A1), B (B2) and E (E3).
1.3. Antitoxin Treatment
Several mechanisms of action can be involved in the neutralization of BoNTs, depending on
whether the antibodies target the HC or LC. For antibodies that target the HC, the neutralization
can occur indirectly in the bloodstream by steric hindrance, impeding the binding of the toxin, or
directly by inhibiting the translocation to the Hn domain of BoNTs. For antibodies targeting the LC,
the neutralization can occur directly by preventing the cleavage of the SNARE complex. Several
studies have previously evidenced antibodies neutralizing BoNT/A by targeting the LC or the HC
but only a few of them are of human or human-like origin and they generally neutralized only one
of the five BoNT subtypes [49–56]. Antibodies targeting the HC of botulinum toxins and inhibiting
cell entry have also been isolated [57,58]. In a former study, recombinant antibody fragments were
isolated from an immune and a non-immune human library against botulinum toxins built from a
volunteer immunized with botulinum toxoid A to E, which yielded single chain Fragment variables
(scFvs) with best affinities and neutralization properties compared with those obtained from the naïve
library [59]. In contrast, very few antibodies neutralizing the BoNT/A LC endopeptidase activity have
been described since only three antibodies of human (4LCA), macaque (2H8) and llama (Aa1) origin
have been reported to date [49,50,60]. It was suggested that the recruitment of immune effectors may
be involved in vivo in the BoNTs-neutralization, even if the LC is targeted [61]. It was also shown that
the combination of antibodies targeting the heavy and the LCs of BoNT/A neutralize synergistically
this toxin [49].
To date, immune and naïve human libraries have been shown to be useful for the isolation of
antibodies neutralizing BoNT/B [49,59,62]. Kalb et al. successfully isolated picomolar antibodies
cross-neutralizing BoNT/B1 and B2 by the targeting of BoNT/B LC [62]. Two of these antibodies, 2B27
and 1B10.1, seemed to inhibit the catalytic activity of some BoNT/B subtypes by interacting with the LC
in vitro, determined by endopeptidase-MS. In those studies, BoNT/B1, B2, B3, B4 and B5 toxin, as a form
of complexes, were neutralized in vitro by a pool of 24 fully human antibodies. These 24 antibodies were
derived from in vitro affinity-improved variants, generated from antibodies initially isolated after the
panning of an immune library, but their neutralization potential was not assessed in in vivo or ex vivo
predictive models. A human IgG (30B) recognizing BoNT/B-HC with a high affinity (1.12 × 10−12 M)
was previously isolated by hybridoma technology starting from the lymphocytes of human volunteers
vaccinated with the pentavalent botulinum toxoid vaccine. This antibody only showed partial inhibition
of BoNT/B1 in vivo as it delayed paralysis, but did not prevent mice mortality [49]. The first report of the
potentially neutralizing human monoclonal antibody against BoNT/B, derived from naïve single-chain
variable fragment (scFv) phage display library against BoNT/B HC domain was reported by Zhou et al.
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but again this report did not include in vivo or ex vivo neutralization studies, and relied exclusively on
in vitro cell-based assay. A more recent study reveals that the human monoclonal antibody called 2B18
neutralizes BoNT/B by the targeting of an epitope in the Hn domain, that is conserved by several
subtypes [63]. To our knowledge there is no publication that presents the neutralization of BoNT/B by
human-like monoclonal antibodies targeting the LC.
Seventeen monoclonal antibodies were previously generated by immunization of BALB/c mice
using a type E toxoid binding to the HC of BoNT/E [64]. Furthermore, the scFv 4E17 was isolated
from human volunteers immunized with a botulinum pentavalent vaccine that binds to an epitope
located at the N-terminus of the HC [63] but no recombinant human-like antibody that neutralizes
BoNT/E in vivo by targeting the LC (BoNT/E-L) has been reported to date.
In this review, we describe the results of the European framework project AntiBotABE (Figure 1).
In this project, several recombinant antibodies neutralizing BoNT/A, B and E in an ex vivo model
and in the in vivo mouse protection assay were isolated, starting from the panning of 6 immune
phage-display libraries of macaque (Macaca fascicularis) origin.
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2. ni al I unization and Antibody Phage-Display Library Construction
In previous studies, macaques were already used for the generation of immune-libraries and
for the isolation of antibody fragments with nanomolar and picomolar affinities. With this strategy,
antibodies neutralizing fungi (e.g., Aspergillus fumigatus), toxins (e.g., tetanus toxin, ricin, and anthrax)
and viruses (e.g., Venezuelan equine encephalitis virus and Simian immunodeficiency virus) were
isolated [1,2,4–6,65–68].
The standardisation of botulinum t xins used to validate animal immunization is described in
detail in Section 3.2. Briefly, the effects of botulinum t xins were assess d by establishing complete
dose respo se curves for the three main botulinum toxin serotypes on phrenic nerve-hemidiaphragm
(MPNH) and titrations curves were established for standard reference antitoxins against the three
major serotypes of botulinum toxins—A, B and E [69,70].
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2.1. Immunization of Macaques (Macaca fascicularis) Using the Non-Toxic and Recombinant HC or LC of
BoNT/A, B or E
Several studies compared the nucleotidic and peptidic sequences of the variable domains of
human and non-human primate antibodies. These studies revealed a close proximity between human,
macaque and chimpanzee antibodies. As it was observed that there is no significant difference between
macaque and chimpanzee antibodies, macaques represent a model of choice for the development of
therapeutic antibodies [47,48,71,72]. In the context of the AntiBotABE project, the strategy was based
on the immunization of macaques because it is easier to obtain with immune-libraries, high-affinity
antibodies specific to epitopes spanned on the whole immunogen [51].
All animal studies presented in this section were given specific approval from the Institut de
Recherche Biomédicale des Armées Ethics Committee (Comité d’éthique de l’Institut de Recherche
Biomédicale du Service de Santé des Armées) under authorization No. 2008/03.0 and were performed
in accordance with all relevant French laws and ethical guidelines.
Six macaques were immunized four times each with the recombinant and non-toxic HC or LC of
BoNT/A1, B2 or E3 [48]. This protocol led to a stable and high titer against the corresponding immunogen,
as determined by ELISA. For the anti-BoNT/A1-LC antibodies, a titer of 1/100,000 was observed against
the BoNT/A1 holotoxin [50]. For anti-BoNT/A1-HC antibodies, a titer of 1/800,000, 1/1,310,000 and
1/40,000 was observed in ELISA against BoNT/A1-HC (the immunogen), BoNT/A1 (holotoxin) and
BoNT/A2 (complex), respectively. For anti-BoNT/B-LC antibodies, a titer of 1/100,000 (BoNT/B2-HC
immunization) or 1/300,000 (BoNT/B2-LC immunization) was observed against the immunogen. For
anti-BoNT/E-HC antibodies, a titer of 1/600,000 against BoNT/E3 holotoxin was observed. Finally, for
anti-BoNT/E-LC antibodies, a titer of 1/600,000 against BoNT/E3 holotoxin was observed [51,73–75].
After the last antigen administration, the macaque bone marrow was iteratively sampled over
a period of up to 20 days, in order to observe an optimal amplification of the DNA encoding the Fd
fragments and the κ LC. At the time of optimal DNA amplification, the retro-amplified DNA was
retained and used for the generation of the antibody immune libraries.
2.2. Phage-Displayed Immune Libraries Construction
Immune-libraries were generated as previously described [1,2,4,65,71–73]. Briefly, the DNA
encoding the Fd fragments and the κLC were separately sub-cloned in pGEM®-T vector and then
sequentially cloned in the pHAL14 or pHAL32 phagemid vector. These phagemid vectors allow the
expression of scFv-pIII fusion protein at the surface of the phage particle. As they contain both bacterial
and phagemid origins of replication, they can replicate as single and double strand phagemids and
they can directly be used for phage-display screening. Each library was packaged in M13KO7 or
hyper-phage. The immune-library directed against BoNT/A1-LC consisted of 3.2 × 108 independent
clones with a full-size insert rate of 80%. This library was packaged with M13K07 or Hyperphage [51].
The immune-library directed against BoNT/A1-HC consisted of 5.45 × 107 unique clones and was
finally packaged in M13K07 helper-phage [73].
The immune-library directed against BoNT/B2-HC consisted of 1× 108 independent clones and was
finally packaged in M13K07 helper-phage. The immune-library directed against BoNT/B2-LC consisted
of 1.1 × 108 unique clones and was finally packaged in M13K07 phage [74]. The immune-library directed
against BoNT/E3-LC consisted of 9.6 × 108 independent clones with a full-size insert rate of 88%.
This immune library was packaged with M13K07, resulting in phage titers of 3.4 × 1013 cfu mL [75].
2.3. Selection of scFv Directed against BoNT/A1 and A2, or B1 and B2 or E3 Subtypes/Serotypes by Multi-Step
Panning and Screening by ELISA
A 3 rounds-panning against holotoxin BoNT/A1 or recombinant BoNT/A-LC was performed
with Hyperphage and M13K07 packaged antibody-phage libraries. For the Hyperphage packaged
library, 6.2 × 103 antibody-phages were isolated against the BoNT/A1 holotoxin after the third and
last round of panning. Using the library packaged in M13K07 phage, 1.3 × 105 antibody were isolated
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against the BoNT/A1. For the panning against the LC, only the M13K07 packaged library was used
and resulted in 5.5 × 108 antibody-phages after the third round of panning. After the last round of
screening, reactivity against BoNT/A1 was analyzed by ELISA on randomly hand-picked antibody
clones. About 100 clones from each panning were expressed as soluble scFv for screening by ELISA.
The binding of those scFv to BoNT/A1 holotoxin and BoNT/A1-LC were tested by antigen ELISA
(data not shown). In total, 69 ELISA positive scFv clones binding to BoNT/A1 were identified. These
clones were sequenced and 22 unique scFvs were revealed suggesting that these scFv may target
different epitopes.
For BoNT/A1 HC, the phage-displayed scFvs library was subjected to 3 rounds of panning
against BoNT/A1 holotoxin with a doubling number of washes after each round (5, 10 then 20 washes).
After each round, only the phage having interacted with BoNT/A1 were eluted. Between the first
and the second round of panning the number of eluted phage decreased from 115,000 (round 1) to
10,000 (round 2), underlining the selection of the small proportion of reactive phage among the whole
immune-library. The reactivity of the phage eluted after each round against BoNT/A1 was assessed in
phage-ELISA. The signal increasing 9-fold between round 1 and 3 confirmed the enrichment in scFvs
highly reactive against the target [73].
To isolate scFvs cross-reacting with BoNT/B1 and B2, the hyper-immune libraries were
subjected to an innovative two-time panning process (classically performed against one immunogen).
The panning was initiated with the holotoxin BoNT/B1 to select scFvs reacting against the fully active
toxin, which is also derived from a different subtype than the subtype used as the immunogen. First, a
three-round panning was performed on BoNT/B1 and then a fourth and last round was performed
against BoNT/B2 to isolate only the cross-reactive antibodies. During the panning, the number of
washes was doubled between the first three rounds and unchanged during the fourth round. One
hundred clones were randomly handpicked after the fourth round of panning against BoNT/B2-HC,
and then sequenced to express the non-redundant and non-recombined scFvs cross-reacting with
BoNT/B1 and BoNT/B2. Ten different scFvs were identified, expressed as soluble scFvs, purified and
their affinities for BoNT/B1 and BoNT/B2-LC were measured. The multistep panning approach was
validated because the number of eluted phage was comparable to that reported in previous studies
and sub-nanomolar scFvs were produced [1,74].
For the library directed against BoNT/E LC, a multi-step panning of four rounds was performed
against BoNT/E3 holotoxin (5, 10, 20 and 40 washes). After each round of panning, the reactivity of
the eluted phage against BoNT/E3 was assessed by phage-ELISA and the signal increased 1.5-fold
between rounds 1 and 4. After the fourth round of panning, 100 scFv-clones were randomly chosen
and the scFv encoding DNA was extracted and sequenced. Eighty-five unique scFvs were observed
and their affinity for in vitro-activated BoNT/E3 was measured [75].
2.4. Further Characterization by Affinity Measurements
Affinity was determined by surface plasmon resonance (SPR, Biacore®, GE Healthcare Europe
Velizy-Villacoublay, France). For the LC of BoNT/A, the affinity of the 22 isolated-scFv was determined.
The majority of them were in the nanomolar range, underlining a high specificity. Three out of 4 scFvs
had a sub-nanomolar range affinity [51]. For anti-BoNT/A1-HC antibodies, the affinity of sixty-four
scFvs was measured against BoNT/A1 and they ranged from 1.3 nM (A1HC49) to 50 nM. The affinity
of the scFv A1HC38 was measured at 1.9 nM with Kon = 6.34× 104 M−1 S−1 and Koff = 1.2× 10−4 S−1.
The twenty-four scFvs (37.5% of all non-redundant and non-recombined scFvs) presenting affinities
better than 10 nM were selected for the neutralization capacity assessments [73].
For the HC of BoNT/B, 10 different scFvs were expressed in E. coli strain HB2151 as soluble
scFvs and their affinities were measured by SPR. The affinities ranged from 2.29 nM (B2-6) to 14.1 nM
(B2-63) for the holotoxin BoNT/B1 and from 0.2 nM (B2-119) to 11 nM (B2-29) for BoNT/B2-HC
with affinities against BoNT/B2-HC (the immunogen) always being more favourable than against
BoNT/B1. The affinity of scFv B2-7 was 5 nM and 0.6 nM, for the holotoxin BoNT/B1 and BoNT/B-HC,
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respectively. For the LC of BoNT/B, affinities for BoNT/B1 ranged from 0.4 nM (BLC3) to 17 nM
(BLC18) for BoNT/B1. Affinities for BoNT/B2-LC were generally less favourable than for the holotoxin
BoNT/B1 [74].
The affinity was measured only for the four anti-BoNT/E3 antibodies that were found inhibiting
in the endopeptidase assay. Their affinity ranged from 0.01 to 9.16 nM [72]. In addition to the affinity
measurements of the selected scFvs, affinity of the germline-humanised IgGs was also measured by
SPR but the data are currently classified by the European Commission [76].
3. In Vitro Evaluations and Ex Vivo Neutralizing Properties of High Affinity scFvs and scFv-Fcs
Antibodies targeting the HC are suspected to block the binding of the toxin to the cell surface,
inhibiting the penetration of the toxin into the cell or the translocation of the LC through endocytosis
vesicles into the cytosol. The antibodies targeting the LC may also have the same action, but only
indirectly by steric hindrance. In addition, antibodies targeting the LC are considered to directly
inhibit the catalytic activity of the light chain. To fully explore the neutralizing capacities, two different
approaches were chosen for the AntiBotABE project: an in vitro endopeptidase approach to explore
the inhibition of the catalytic activity by antibodies targeting BoNTs LC and the ex vivo approach to
evidence a broader neutralizing action of the antibodies by preventing the binding and translocation
of the BoNTs. The scFvs initially found to be binding BoNTs were converted into scFv-Fc antibodies
for the assessment of their neutralizing properties. For example, a murine IgG2C-Fc was used for the
anti-BoNT/A1 binders, resulting in a chimeric antibody. Nineteen of the 23 anti-BoNT/A1 binders
were re-cloned and produced as scFv-Fc with a murine IgG2c-Fc part. The yield of the remaining four
antibodies was too low for further analysis. The antigen binding of the 19 scFv-Fc was compared and
validated by ELISA on immobilized BoNT/A LC before in vitro and ex vivo evaluations (Figure 2).
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initial study [50]. With regard to the scFv-Fc concentration inhibiting 50% of BoNT/A1 in vitro, the
SEM120-IIIC4 gave the highest level of inhibition. The molar ratio of antibody to toxin at which
50% inhibition of endopeptidase activity was found to be almost 0.5:1 for the SEM120-IIIC4 antibody.
All antibodies inhibiting endopeptidase more efficiently than 2H8 and with little or no background
signal were selected for further ex vivo studies [51].
The molar ratio (antibody to toxin) at which a 50% inhibition of endopeptidase activity was
observed was assessed for all tested antibodies to compare their inhibitory profiles. The molar ratio
for the 2H8 produced as a scFv was 64,000:1, [51] while, a 50% inhibition was observed at a molar
ratio of 6500:1 for the 2H8 when produced in the scFv-Fc format, presumably due to an avidity effect.
Nevertheless, the best molar ratios were those obtained for SEM120-IIIC4 (0.5:1), SEM120-IID5 (1:1)
and SEM120-IIIC1 (5:1) as scFv-Fc antibodies. Those molar ratios were far more favourable than for
the human 4LCA IgG reported previously, yielding 63% inhibition of BoNT/A endopeptidase activity
with a corresponding molar ratio of 10,000:1 [49] and for the llama antibody Aa1 exhibiting a 50%
inhibition only against the LC of BoNT/A and with a molar ratio of 200:1 [60].
The in vitro endopeptidase assay was performed against both BoNT/B1 and BoNT/B2 subtypes in
order to select cross-neutralizing scFvs directed against the BoNT/B2-LC. Due to their low nanomolar
affinities, 26 scFvs were assessed for their inhibition properties in the VAMP2 endopeptidase assay.
Six (23%) scFvs inhibited the catalytic activity of 0.2 LD50 mL−1 complex BoNT/B2, and only two of
these (7.6%) also inhibited 30 LD50 mL−1 of pure BoNT/B1 subtype. The inhibition of BoNT/B1 and
BoNT/B2 catalytic activity observed for all scFvs was dose-dependent and considerably improved
when the more stable scFv-Fc bivalent format was used since it is more similar to the IgG format.
This observation was consistent with our previously published studies showing a reduced inhibition
ratio with scFv-Fcs antibodies targeting BoNT/A-LC in comparison to the corresponding scFv format.
In addition, similar findings were obtained for the antibody targeting the BoNT/E-LC [75].
The 38 selected scFv targeting BoNT/E3 were also assessed for their inhibition capacities in the
SNAP-25 endopeptidase immunoassay. The best scFv: ELC76 inhibited the endopeptidase activity
of BoNT/E3 at a molar ratio of scFv to toxin of 14,765:1 (IC50 of 33.8 nM). The scFvs inhibiting the
toxin endopeptidase activity were selected for further analyses using the ex vivo MPNH assay and
affinity measurements.
3.2. Ex Vivo Screening of Anti-BoNT HC and Anti-BoNT LC Antibodies as scFv or scFv-Fc in the Mouse
Phrenic Nerve Hemidiaphragm Paralysis Assay
Preparation of standardized botulinum toxins and anti-toxins: Purified type A1 and B1 hemagglutinin
free toxins were purchased from Metabiologics Inc. (Madison, WI, USA) and diluted to 20,000 LD50 mL−1
in gelatin (0.2% w/v) phosphate buffer (GPB). Concentrated pure hemagglutinin free botulinum type
E3 from Metabiologics was trypsinised and diluted in GPB, pH 6.5. Purified type A2 hemagglutinin
free and complex toxins were purchased from Metabiologics Inc. (Madison, WI, USA) and diluted to
500,000 LD50 mL−1 in GPB pH 6.5. A commercially available equine polyclonal F(ab’)2 preparation
(Novartis Vaccines, Marburg, Germany) was used as a positive control in neutralization assays.
For standardization of the BoNTs, the effects of botulinum type A, B and E toxins on MPNH were
assessed by establishing complete dose response curves for the three main botulinum toxin serotypes.
The use of Balb/c in-bred mice greatly improved the standardization of the hemidiaphragm assay due
to very low variability in the 50% paralysis time measurements whatever the dose or serotype of the
botulinum type. In addition, the increased precision of the assay using in-bred mice allowed more
accurate evaluations of toxin or neutralizing antitoxin levels.
Additional work was performed with botulinum toxin subtypes A2 and B2 to establish the dose
paralysis curve in order to test new scFvs directed against A2 and B2 subtypes. Titration curves were
established for standard reference antitoxins against the three major serotypes of botulinum toxins A,
B and E. Series of monovalent standard antitoxins and polyvalent licensed and experimental products
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were previously tested which confirmed excellent correlation between the ex vivo MPNH assay and
the in vivo mouse bioassay.
The preliminary in vitro evaluations of selected antibodies had to be completed with ex vivo
neutralization capacity assessments in order to assess their neutralizing potential in subsequent in vivo
studies. In the MPNH assay, the in vivo respiratory paralysis caused by BoNT is closely reproduced
ex vivo in mouse hemi-diaphragmatic tissues [69]. In the neutralizing activity assessment of new
antibodies against the main toxin serotypes A, B and E, this ex vivo assay approach provided results
highly consistent with those of the mouse in vivo assay [70].
In the MPNH ex vivo model, the time to reach 50% paralysis after the addition of the
mixture of botulinum toxin/scFv-Fc is assessed by fitting to the linear part of the paralysis curve.
The neutralization potential of the scFv-Fc antibodies is directly correlated with their ability to prolong
the 50% paralysis time by delaying BoNT-induced paralysis onset. A greater antibody neutralizing
potency is associated with a longer time period required to reach 50% paralysis of the hemidiaphragm
tissue while exposed to the same dose of toxin.
To confirm the validity of the neutralization properties of the antibodies showing inhibitory
properties against BoNT/A LC in the endopeptidase assay, the ex vivo neutralization capacity of eight
inhibitory antibodies was tested using 30 µg/mL of each in the scFv-Fc format. The positive control
was a trivalent equine F(ab’)2 polyclonal serum and the negative control was a anti-ricin antibody
43RCA. Five of the eight antibodies initially selected (SEM120-IID5, SEM120-IIIC1, SEM120-IIIC4,
SEM95-G8 and SEM120-IE4) strongly neutralized BoNT/A1 by significantly delaying the BoNT/A1
toxin induced paralysis. Each of the five antibodies doubled the 50% paralysis time (50% PT), i.e.,
202 min, 200 min, 188 min, 181 min and 173 min for SEM120-IID5, SEM120-IIIC1, SEM120-IIIC4,
SEM95-G8 and SEM120-IE4, respectively. Moderate levels of neutralization of the same toxin were
obtained in the hemidiaphragm assay for the SEM119-IE2 (50% PT: 164 min) while the SEM120-IVC5
displayed weak neutralization ability (50% PT: 116 min) (Figure 3). For future immunotherapeutic
purposes, the best antibody was produced as a complete germline humanized IgG.
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paralysis time with BoNT/A1 was delayed by 115 minutes  in presence of 20 mIU mL−1 of positive 
control. Among  the  24  scFvs  tested,  3  efficiently  neutralized  BoNT/A1  at  20  LD50 mL−1  at  the 
concentration of 27.25 μg mL−1 (A1HC17), 5.21 μg mL−1 (A1HC38) or 12.25 μg mL−1 (A1HC45). These 
scFvs delayed the 50% paralysis time by more than 145 minutes (145%), by 164 minutes (164%) and 
by 95 minutes (95%), respectively. The three scFvs neutralizing BoNT/A1 were then tested at a high 
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For the anti-BoNT/A HC antibodies, all scFvs with affinities better than 10 nM against BoNT/A1
HC were tested in the ex vivo MPNH assay, to identify those neutralizing BoNT/A1 holotoxin and
cross-neutralizing BoNT/A2 toxin complex. The best scFv cross-neutralizing BoNT/A1 and BoNT/A2
was then finely analyzed against BoNT/A1 and BoNT/A2, in decreasing doses of the scFv. The 50%
paralysis time with BoNT/A1 was delayed by 115 min in presence of 20 mIU mL−1 of positive control.
Among the 24 scFvs tested, 3 efficiently neutralized BoNT/A1 at 20 LD50 mL−1 at the concentration
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of 27.25 µg mL−1 (A1HC17), 5.21 µg mL−1 (A1HC38) or 12.25 µg mL−1 (A1HC45). These scFvs
delayed the 50% paralysis time by more than 145 min (145%), by 164 min (164%) and by 95 min (95%),
respectively. The three scFvs neutralizing BoNT/A1 were then tested at a high concentration against
BoNT/A2 in the complex form. At concentrations of 20 µg mL−1 (A1HC17) or 15 µg mL−1 (A1HC38
and A1HC45), the 50% paralysis time was delayed by 115 min (97%, A1HC17), more than 220 min
(188%, obtained by extrapolation, A1HC38) and 45 min (38%, A1HC45) [73].
As the scFv A1HC38 was the most efficient cross-neutralizing scFv, it was selected for further
characterization at lower dilutions against BoNT/A1 and BoNT/A2. At concentrations of 0.5 and
1 µg mL−1, A1HC38 delayed the 50% paralysis time by 45 and 120 min, respectively (45% and 120%
delay in paralysis, respectively). The minimum neutralizing concentration was considered to be close
to 0.5 µg mL−1. At concentrations of 7 and 5 µg mL−1, A1HC38 delayed the paralysis induced by
BoNT/A2 by more than 227 min (more than 192% delay in paralysis) and by 65 min (55% delay in
paralysis), respectively [73].
These results are quite promising since efficient neutralization of BoNT/A usually requires
the association of several neutralizing antibodies and because neutralization properties of the
A1HC38 were even stronger than with the polyclonal F(ab’)2 antitoxin. Antibodies targeting the
HC could neutralize the toxin by different mechanisms, mainly by preventing toxin binding and its
internalization into the motor neurons, but they also could indirectly inhibit the catalytic activity, by
steric hindrance. The affinity of A1HC17 and A1HC38 were measured and were equal to 4.79 nM
and 1.9 nM, respectively, and it is interesting to note that no strict correlation between high affinity
and neutralization properties was observed since the four best scFvs in terms of affinities were
not neutralizing.
The scFvs BLC3 and BLC42 were also tested in the ex vivo MPNH assay, but their neutralization
capacities were found to be weak (data not shown). However, the use of a more stable version of the
BLC3 (scFv-Fc) resulted in much stronger neutralization of pure BoNT/B1 (100 LD50 mL−1) as well as
complex BoNT/B2 (0.2 LD50 mL−1). Neutralization of BoNT/B2 subtype, but not of BoNT/B1, by
scFv BLC3 was better than that for the commercial polyvalent F(ab)2 antitoxin, at 20 mIU mL−1, which
increased 50% paralysis time by about 100 min for both subtypes.
Initial screening of all the anti-BHC scFvs in the MPNH assay identified 6 scFvs with some
inhibitory properties against BoNT/B1 (100 LD50 mL−1), with scFv B2-7 showing the strongest
neutralization at 29 µg mL−1 (comparable to that observed with commercial polyvalent F(ab)2 antitoxin
at 20 mIU mL−1). B2-7 was thus selected for further characterisation against 0.2 LD50 mL−1 of complex
BoNT/B2 (equipotent paralytic dose to 100 LD50 mL−1 of pure BoNT/B1). The dose response for
neutralization of complex BoNT/B2 by scFv B2-7 showed a 52 min delay of the 50% paralysis time,
representing 23% inhibition at 5.0 µg, which increased to a 374 min delay and 73% inhibition at 10 µg
of scFv B2-7.
Strong neutralization was also confirmed with the scFv-Fc fusion form of the B2-7 against the
same concentrations of BoNT/B1 and BoNT/B2 subtypes, inducing a 67 min and 80 min prolongation
of the 50% paralysis time at 1.0 and 30 µg mL−1, respectively. Hence, the B2-7 is the most promising
candidate for further development targeting the HC of BoNT/B [74] (Figure 4).
For the anti-BoNT/E antibodies, to confirm that the antibodies inhibiting the endopeptidase
activity of BoNT/E3 in vitro do have toxin neutralization properties, their neutralization capacity
against BoNT/E3 was tested in the ex vivo MPNH assay. Only ELC18, ELC51 and ELC76 were tested
ex vivo [75].
When the same three scFv were tested for neutralization of 20 LD50 mL−1 of pure BoNT/E3
(330 pg/mL) in the MPNH, the scFv ELC18 was identified as most neutralizing (445 min paralysis
time) and further lower doses were studied. Significant neutralization (at least 25% inhibition of
activity, 164 min paralysis time) was confirmed with as low as 0.3 nM of scFv ELC18, and almost 50%
inhibition observed at ~3.3 nM. This represents a more favourable neutralization profile compared to
in vitro inhibition with molar ratio of ~1500:1 (an increase of 33-fold). For further analysis ELC18 was
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converted into the scFv-Fc antibody format and tested at different dilutions in the ex vivo paralysis
assay where at lowest concentration of 0.9 nM a 50% paralysis time of 237 min was achieved and
represents a molar ratio (scFv-Fc:toxin) of ~393:1. See the summary table demonstrating affinity for the
in vitro endopeptidase (for LC only) and ex vivo studies results for selected scFv or scFv-Fc antibodies
(Table 1).Toxins 2017, 9, 309    12 of 25 
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Table 1. Affinity, in vitro inhibition and ex vivo neutralization properties of selected scFvs or scFv‐
Fcs. 
Antigen  Antibody  Format
In Vitro
Inhibition: IC 
50 (nM) 
Ex Vivo Neutralization: 
Neutralizing 
Concentration 50% (nM) 
Affinity 
(KD, nM) 
BoNT/A LC  SEM120‐IIIC1  scFv‐Fc 10  1000  0.82 
BoNT/A HC  AHC38  scFv  n/a  33  1.9 
BoNT/B LC  BLC3  scFv‐Fc 66  66  0.4 
BoNT/B HC  B2‐7  scFv  n/a  >1000  4.8 
BoNT/E LC  ELC18  scFv  112  3.3  0.58 
BoNT/E HC  ‐  n/a  n/a  n/a  n/a 
BoNT/E HC: n/a due to lack of neutralization. 
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the mouse in vivo flaccid paralysis model—both individually and in combination for a synergistic 
Figure 4. Neutralization activity in MPNH of scFv-Fc B2-7 targeting BoNT/B-HC. Modified figure
from our previous publication: Rasetti-Escargueil et al. 2015 [74].
Regarding BoNT/E3 HC, ex vivo screening of the 40 scFvs in the hemidiaphragm paralysis assay
did not identify any scFvs with inhibitory properties against BoNT/E3 toxin when 20 LD50 mL−1
(330 pg/mL) of pure E3 toxin was used. Potential synergistic effects were also assessed: twenty-five of
non-competing scFvs were identified, paired and tested, but they did not show neutralizing capacities
against BoNT/E3 while the positive control polyclonal antibody F(ab)2 strongly inhibited BoNT/E3 at
20 mIU/mL in the ex vivo MPNH (data not shown).
Table 1. Affinity, in vitro inhibition and ex vivo neutralization properties of selected scFvs or scFv-Fcs.
Antigen Antibody Format In Vitro Inhibition:IC 50 (nM)
Ex Vivo Neutralization: Neutralizing
Concentration 50% (nM)
Affinity
(KD, nM)
BoNT/A LC SEM120-IIIC1 scFv-Fc 10 1000 0.82
BoNT/A HC AHC38 scFv n/a 33 1.9
BoNT/B LC BLC3 scFv-Fc 66 66 0.4
BoNT/B HC B2-7 scFv n/a >100 4.8
BoNT/E LC ELC18 scFv 112 3.3 0.58
BoNT/E HC - n/a n/a n/a n/a
BoNT/E HC: n/a due to lack of neutralization.
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3.3. Isolation of the Most Promising Antibody Combinations (Anti-BoNT/HC and Anti-BoNT/LC Directed
against the Same Serotype) Using the In Vivo Flaccid Paralysis Assay, Synergistic Protection Assessment,
Epitope Characterization and Affinities Measurements
The BLC3 and B2-7, targeting BoNT/B-LC and HC respectively, were tested in scFv-Fc forms in
the mouse in vivo flaccid paralysis model—both individually and in combination for a synergistic
neutralizing effect—against complex BoNT/B2 (0.2 LD50 per dose). Complete protection was achieved
with 25 and 2.5 µg of BLC3, whereas B2-7 did not fully protect mice at 25 µg per dose, but lowered the
intensity of paralysis. Those neutralization results were comparable at both 24 h and 48 h observation
times. Additional neutralization studies with higher concentrations (50 µg and 100 µg) of scFv B2-7
demonstrated a similar effect with no benefit of dose increase. However, the combination of BLC3 and
B2-7 fully protected mice in vivo where protection was not observed by each antibody alone (0.25 µg
of each antibody) confirming effective and substantial synergistic effect [74] (Figure 5).
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4. Germline-Humanization and In Vivo Characterization of the Selected Antibodies
The development of neutralizing human-like scFv-Fcs targeted against LCs and HCs of BoNT/A,
B and E has been described in our previous studies [51,73,74]. However, for future medical
applications optimal tolerance in humans has to be ensured when using such antibodies and several
humanization methods have been described [77]. One method especially for antibodies derived from
non-human primates (NHP)—germline-humanization—is based on the modification of the NHP
antibody framework regions (FR) to increase the level of identity with the FRs encoded by the closest
human germline gene sequences [78]. Germline humanization consists of series of mutations in the
framework regions (FRs) of non-human primate (NHP) antibody to obtain humanized FRs while
preserving high epitope affinity and neutralization capacity. It has been shown that human germline
FRs of IgM antibodies are better tolerated by the immune system than FR sequences derived from IgG
antibodies, which carry somatic hypermutations resulting from affinity maturation that probably form
immunogenic sequences [79,80].
4.1. Generation of Variants of the Germline Humanized Antibodies and Identification of the Most Promising
Germline-Humanized Variant for Each Library
For optimal immune tolerance in humans, the framework regions of macaque antibodies should
be very similar to the corresponding human germline sequences. The potential immunogenicity of
antibodies can be estimated by calculating the level of identity of the corresponding framework regions
to the most similar human germline-encoding framework regions. This identity level of antibodies is
also known as the germinality index (GI) [3].
In our previous studies, we reported the generation of neutralizing scFv and scFv-Fc derived
from macaques against BoNT/A, BoNT/B and BoNT/E: SEM120-IIIC1 (anti-BoNT/A LC), A1HC38
(anti-BoNT/A HC), BLC3 (anti-BoNT/B LC), B2-7 (anti-BoNT/B HC) and ELC18 (anti-BoNT/E
LC) [51,73,74]. Based on the physicochemical classes of the amino acids, differences in the FRs were
classified as very similar, similar, dissimilar or very dissimilar AA according to IMGT [81].
Twenty-two scFv isolated by panning for isolation of anti-BoNT/A1 LC antibodies were
sequenced by GATC Biotech (Konstanz, Germany) and compared with human germline sequences,
with the IMGT/V-QUEST online tool from the International ImmunoGeneTics information system®
(IMGT, Montpellier, France) [82]. This tool identifies the human germline sequences most similar to
any given variable region and calculates the germinality index (GI), defined as the percentage identity
between a given framework region (FR) and the most similar human germline sequence. GI indirectly
predicts the tolerance of a VH or VL sequence, based on the assumption that germline encoding
sequences are the best tolerated, as they are part of the IgM immunoglobulins. The GI values of the
23 scFv ranged from 79.1% to 92.3% for VH and from 77.5% to 92.1% for VL. For comparison, the
mean GI values of 100 unpublished human scFv from a naïve scFv library (HAL7/8) 43 were 96.6% for
VH and 94.8% for VL. The germline humanization of macaque antibodies is a potentially promising
method for increasing immune tolerance for human treatment. An analysis of the human germline
genes most similar to the genes encoding the 22 selected scFv in addition to 2H8 showed that VH and
VL sequences were highly diverse. The germinality index (GI) for each VH and VL was calculated
and provided an indication of the identity between framework regions of the selected scFv and those
encoded by the most similar human germline genes, as a percentage [51].
After the isolation and the sequencing of the scFvs targeted against HC of BoNT/A1, a
computational analysis using IMGT/V-QUEST tool was performed to retrieve the human germline
sequences closer to the sequence of the 24 selected scFvs. The use of three IGHV family genes
(families IGHV-1, -3 and -5) was observed. These VH were combined to four different IGHJ family
genes (families IGHJ-2, -4, -5 and -6). Regarding LCs, the use of two different IGKV genes (1 and 3)
was observed: IGKV1-39*01 and IGKV1-16*01 (5 occurrences each), IGKV1-17*01 (4 occurrences),
IGKV1-27*01, IGKV1-13*02 and IGKV1-9*01 (2 occurrences each) and finally one occurrence of
IGKV1D-13*01, plus three single occurrences of IGKV3 (IGKV3-7*02, IGKV3-11*01 and IGKV3-20*01).
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These IGKV genes are also combined to different IGKJ family genes (families IGKJ-1, -2, -3 or -4).
The GI of the 24 best scFvs ranged between 81.13% and 87.72%, underlining their high identity level
with human sequences and thus their likely low immunogenicity. The G-score is another parameter
that could indirectly predict the tolerance of the scFv, but it is based on the comparison with the
expressed genes and not with germline genes [71,72]. The G-scores of the 24 selected scFv were also
determined and ranged between −1.01 and −2.37. Even if the G-score of the LCs of A1HC34, A1HC45
and A1HC65 were positives then all mean G-score were negatives.
For comparison, the mean GI values of 100 unpublished human scFv from naive antibodies
libraries are 96.6% for VH and 94.8% for VL [51]. The mean G-score of A1HC17 and A1HC38 were
−1.53 and −1.75, respectively, thus they were respectively “as human” as 6% and 4% of the human
antibodies belonging to the same germline gene family present in the Kabat database. A sequence
with a G-score equal to zero has the same identity level with human expressed antibodies than the
average identity observed when human antibodies are compared between them. A sequence with a
negative G-score presents lower than average identity level and should be humanized to increase its
tolerance. Because A1HC17 and A1HC38 cross-neutralized the BoNT/A1 and BoNT/A2 sub-types,
they are good candidates for a future clinical development, especially in combination with the anti-LC
antibody SEM120-IIIC1.
For anti-BoNT B HC antibodies, the IMGT/V-QUEST tool was used to analyse the DNA sequence
of the isolated scFv to identify the V, D and J genes from which they would have derived if they
had been of human origin. The percentage of similarity between the framework regions of each scFv
peptide sequence and the most similar human germline peptide sequences (percentage referred to as
Germinality Index, GI) was calculated for each isolated scFv and averaged (average of the antibody
heavy and LC of the framework regions of each scFv). For the 10 isolated scFvs, GIs ranged from
80 % to 89% and the mean GI was 82.7%, which highlights their human-like character. The G-score,
which evaluates the “humanness,”and thus predicts scFv potential immunogenicity, was calculated
for each VH and VL region and averaged for each scFv. The scFv mean G-scores for the 10 selected
scFvs ranged from −0.60 to −1.87, with a mean value equal to −1.45. Similarly, for the library directed
against BoNT/B2-LC, sequences identified after clones sequencing were subjected to a computational
analysis. The GIs of the 26 isolated scFvs ranged from 75.82% to 87.91% for the antibody HCs and
from 79.77% to 84.09% for antibody LCs, resulting in an average value for the whole scFv molecule
of between 77.79% and 86%. The mean G-scores for 26 selected scFvs ranged between −1.0035 and
−2.746, underlining that some scFvs are close to human antibody sequences.
After sequencing of scFvs targeting BoNT/E3 LC, analysis using IMGT/V-QUEST tool was
performed, to retrieve the human germline V, (D), J genes most similar to the 38 selected scFv that were
chosen for further in vitro analysis. Almost all HC V genes were dominated by IGHV4 gene family,
with exception of 2 occurrences of IGHV1 and IGHV3 gene family. These genes were combined with
representatives of all IGHD genes and IGHJ genes. The diversity of the LC was limited due to the
presences of mostly IGKV1 genes with only one occurrence of IGKV7. These genes were combined
with nearly all IGKJ genes. The Germinality Index (GI) for each VH and VL were calculated using
IMGT/DomainGapAlign and provided an indication of the identity between framework regions of
the selected scFv and those encoded by the most similar human germline genes, as a percentage. The
average GI-values for the all 38 scFv were 86.9% (VH) and 89.4% (VL). Out of the three neutralizing
scFv, ELC76 was the most human-like antibody fragment with a mean GI equal to 91.2% (87.9% for VH
and 94.4% for VL) followed by ELC18 with 87.8% (85.7% for VH and 89.9% for VL). For comparison,
the average GI value of 500 scFv isolated from the human naïve antibody gene library HAL7/8 [83]
was 95.7%. The high humanness of the isolated antibodies against BoNT/E3 predicts a high tolerance
as is the case with previous studies using the chimeric antibody lumiliximab, consisting of the variable
regions of a macaque combined to human constant regions and showing high tolerance [84,85]. Table 2
demonstrates the GI% change for the five selected antibodies.
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Table 2. Germinality indexes (GI %) of selected scFvs or scFv-Fcs.
Antigen Antibody Format Germinality Index (GI %)
BoNT/A LC SEM120-IIIC1 scFv-Fc 86.8 (VH)–87.6 (VL)
BoNT/A HC AHC38 scFv 86.5 (VH)–84.4 (VL)
BoNT/B LC BLC3 scFv-Fc 85.7 (VH)–85.7 (VL)
BoNT/B HC B2-7 scFv 85.7 (VH)–77.2 (VL)
BoNT/E LC ELC18 scFv 85.7 (VH)–89.9 (VL)
BoNT/E HC - n/a n/a
4.2. Expression of the Selected Germline-Humanized Variants as Full-Lengths IgGs
In a first step towards the humanization of the selected antibodies, we exchanged the AA in
the FRs of SEM120-IIIC1, A1HC38, BLC3 and B2-7 with their human counterpart classified as very
similar AA and similar AA. The resulting humanized variable domains were named hu1VH and
hu1VL. We included the AA classified as dissimilar AA, resulting in the humanized variants hu2VH
and hu2VL. In the case of SEM120-IIIC1, we decided to exchange the AA that was classified as very
dissimilar AA, resulting in the humanized Variants hu3VH and hu3VL and modelled each variant using
WAM antibody modelling [86]. In the next step, the humanized variable domains were all combined,
including the parental VH and VL and produced as scFv-Fc. The resulting humanized variants were
termed hu1SEM120-IIIC1 up to hu16SEM120 IIIC1. The antigen bindings of the 16 humanized variants
were compared and validated by ELISA tests using immobilized recombinant LC or HC of BoNT and
by surface plasmon resonance (SPR) analyses using holotoxin. Based on the ELISA and SPR analyses
the hu8SEM120-IIIC1 was selected for further in vivo studies [87] (Figure 7).
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The resulting humanized antibody variants were named hu1A1HC38 up to hu8A1HC38, hu1BLC3 up
to hu8BLC3 or hu1B2-7 up to hu8B2-7. The antigen binding of the eight humanized variants of A1HC38,
BLC3 and B2-7 was compared and validated by ELISA using recombinant LC and HC of BoNT/A or
B. Based on these results, the hu8A1HC38, hu8BLC3 and hu8B2-7 variants were selected for further
in vivo studies. The average GI of 500 scFv, isolated out of the naïve human antibody gene library
HAL7/8, was 96.8% (VH), 95.4% (VL lambda) and 94.8% (VL kappa). With GI values of 95% (hu8BLC3),
94.4% (hu8B2-7), 94.5% (hu8SEM120-IIIC1) and 94.9% (hu8AHC38) the germline-humanized variable
domains are as human as naïve human germline derived variable domains.
For the humanization process of ELC18 we used a multistep approach. In a first step, we designed
humanized variants of the variable domains of ELC18 by exchanging AA in the FRs differ from the
human germline sequence with their human counterpart classified as very similar and similar AA.
The resulting variable domains were named hu1VH and hu1VL. We then included the AA classified as
dissimilar AA, resulting in the humanized variants hu2VH and hu2VL, and combined each variable
domain with each other, including the parental VH and VL. By exchanging this AA, the GI value of
the humanized antibodies rose to 97.3% (hu8ELC18). To validate the quality of the humanization
process, we produced eight distinct variants as scFv-Fc antibodies and the antigen binding of the
eight humanized variants, and the parental ELC18 was compared and validated by ELISA using
immobilized BoNT/E LC (Figure 8). No significant difference in the antigen binding was observed
between the humanized variants and the parental ELC18 (no reactivity against BSA, data not shown).
For hu8ELC18, only 5 AA of the parental antibody were retained and classified as very dissimilar
AA. The average GI of 500 scFv isolated out of the naive human antibody gene library HAL7/8 was
96.8% (VH), 95.4% (VL lambda) and 94.8% (VL kappa). With the highest GI value of 97.3% of all
ELC18 variants, hu8ELC18 was selected for further in vivo studies. Therefore, scFv-Fc hu8ELC18 was
re-cloned and produced as human IgG to obtain a ‘better than human’ IgG [76].
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Assays, Individually and in Combination
The selected IgGs targeting BoNT/A LC (hu8SEM120-IIIC1) and HC (hu8A1HC38) were tested
in vivo in the mouse flaccid paralysis protection model both individually and in combination, for
synergistic effect against pure BoNT/A1 (0.4 LD50 per dose, 1.74 pg) toxin. The hu8A1HC38, selected
IgG targeting the HC of BoNT/A1 toxin, provided complete protection at 100 µg, 50 µg and 10 µg per
dose while only partial protection was observed at all lower doses tested (5 µg and 1 µg per dose). The
hu8SEM120-IIIC1, selected IgG targeting the LC of BoNT/A1 did not fully protect against the paralysis
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induced by BoNT/A1 toxin, even at 100 µg of IgG per dose. Any dose of this antibody between 100 µg
and 5 µg provided similar partial protection against BoNT/A1 induced paralysis with no benefit of
dose increase. However, when these two IgGs were combined as mixture of hu8SEM120 IIIC1 and
hu8A1HC38, full protection was observed at all doses used. The lowest dose ensuring full protection
from in vivo paralysis was 0.1 µg of each IgG in combination (0.2 µg total IgG), whereas full protection
was not observed at 1.0 µg of both antibody alone, confirming strong synergy between IgGs targeting
the LC and the HC.
The selected IgGs targeting the BoNT/B LC (hu8BLC3) and HC (hu8B2-7) were also tested
individually and in combination for synergistic effect against in vivo paralysis induced by complex
BoNT/B2 (0.2 LD50 per dose). Complete protection was achieved with hu8BLC3 at 100 µg, 50 µg and
10 µg per dose and partial protection with two further 10-fold dilutions whereas hu8B2-7 antibody
did not significantly protect mice at any of the concentrations used in this study from 100 µg to 0.1 µg
per dose. However, the combination of hu8B2-7 and hu8BCL3 fully protected mice in vivo at 0.25 µg
dose of each IgG (0.5 µg total IgG) where protection was not observed for each antibody alone at
1.0 µg dose.
To further investigate the in vivo neutralizing potency of the antibodies, the selected IgGs targeting
BoNT/A LC (hu8SEM120-IIIC1) and HC (hu8A1HC38) were tested in vivo in mouse lethality assay
both individually and in combination for a synergistic effect against complexed form of BoNT/A1
(0.4LD50, 1.4 pg per dose). Although partial protection was achieved with 25 µg and 2.5 µg of
hu8SEM120-IIICI or 2.5 µg of hu8A1HC38, respectively, complete neutralization of BoNT/A1 lethal
activity was only obtained by combining both antibodies. The lowest fully protective dose was 2.5 µg
of each IgG (5 µg total IgG), whereas 25 µg of individual antibody only induced a partial protection or
survival with strong symptoms of botulism intoxication (hu8A1HC38), thus confirming the synergistic
effect between the two antibodies.
The selected IgGs targeting the BoNT/B LC (hu8BLC3) and HC (hu8B2-7) were also tested
individually and in combination for synergistic effect against lethality induced by complex BoNT/B2
(0.2 LD50 per dose). Doses of 25 µg and 2.5 µg of hu8BLC3 (anti-BoNT/B LC) provided partial protection
against complex BoNT/B2 while extremely weak protection was observed with the same doses of hu8B2-7
(anti-BoNT/B HC) tested individually. However, the combination of hu8B2-7 and hu8BLC3 fully protected
mice in vivo at 2.5 µg dose of each IgG (5 µg total IgG). Further reduced doses (0.25 µg of each IgG) still
induced 50% protection against 5 MLD50 of BoNT/B2 (Figure 9).
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hu8ELC18 protected against 5 mouse lethal dose (MLD) in a mouse protection assay and complete
neutralization of 1 LD50 of pure BoNT/E toxin was achieved with 8 ng of hu8ELC18 in mouse
paralysis assay. Furthermore, hu8ELC18 protected mice from 5 MLD if injected up to 14 days prior to
intraperitoneal BoNT/E administration [76] (Figure 9).
5. Output of the AntiBotABE Project
In the context of the AntiBotABE project, a previously successfully strategy was used to isolate
neutralizing antibodies directed against the LC of BoNT/A, B and E and HC of BoNT/A and B
(Figure 10).
Six immune phage-display libraries were constructed starting from macaques (Macaca fascicularis)
immunized with a non-toxic recombinant fragment corresponding to BoNT/A1-HC, BoNT/A1-LC,
BoNT/B2-HC, BoNT/B2-LC, BoNT/E3-HC and BoNT/E3-LC. The screening of immune libraries led
to the isolation of several neutralizing scFvs except for the library directed against the heavy chain of
BoNT/E3. Interestingly, antibodies that cross-neutralized both subtypes A1 and A2 of BoNT/A and B1
and B2 of BoNT/B were isolated. Such cross-neutralizing antibodies are highly sought-after in therapy
to expand the therapeutic spectrum of each single antibody while decreasing the number of antibodies
required to develop a wide spectrum neutralizing mixture. To ensure excellent bioavailability and
tolerance the antibodies were germline-humanized then reformatted as full-sized IgG and successfully
tested in vivo.
Protective antibody combinations against BoNT/A and BoNT/B were developed. For BoNT/E,
the anti-LC antibody alone was highly protective. The combination of these five antibodies as
oligoclonal antibody cocktail can be clinically developed for regulatory approval as a therapy.
Studies on recombinant antibodies neutralizing BoNT/B and E by targeting their light chains
have not been published to date. Our studies demonstrated that scFv-Fc BLC3 at doses as low as 2.5 µg
fully protected mice from paralysis induced by 0.2 LD50 of BoNT/B2 toxin. BLC3 demonstrated an
affinity to the holotoxin BoNT/B1 that was over 100-fold higher than to the non-toxic immunogen,
BoNT/B2-LC, which also suggests a preference to conformational epitopes on the whole toxin, and in
turn may also contribute to its higher potency in vivo. High affinity of short chain antibody fragments
is a key element of in vivo efficacy as previously reported for antibodies against BoNT/A-HC and
LC [88].
An interesting observation was made regarding the anti-BoNT/B2 antibodies since we initially
expected that the main protective effect against BoNTs would be based on the binding of the HC, which
is responsible for receptor binding and translocation of the LC into the cytoplasm. The protective effect
of the anti-LC antibody hu8BLC3 could be caused by binding an epitope close to the HC that interacts
with receptor binding or inhibits the translocation of the LC into the cytoplasm. It is also possible that
hu8BLC3 would be still blocking the endopeptidase activity of the LC in the cytoplasm.
To our knowledge, no recombinant human-like antibody neutralizing BoNT/E by targeting
the LC (BoNT/E-LC) has been reported to date. Only neutralizing antibodies targeting the HC of
BoNT/E were described, such as 4E17 isolated from a human immune library targeting a conserved
epitope of the BoNT translocation domain [63], or BMR2, a single domain VHH from dromedary
recognizing the binding domain of BoNT/E [89]. The anti-BoNT/E IgG hu8ELC18 showed high level
of neutralization capacity of 5 MLD/mouse BoNT/E at concentrations as low as 0.0025 µg IgG/mouse.
We also observed that hu8ELC18 showed protection when administered up to 14 days prior to BoNT/E
challenge which suggests preventive effects [76]. This newly developed germline humanized IgG
hu8ELC18 is predicted to have high tolerance in humans, can be produced in high quantities without
the use of animals, and may therefore serve as a better therapeutic option to treat human botulism
compared to HBAT [90].
The protection observed with the five antibodies isolated is outstanding, because it was achieved
without affinity-improvement engineering. As a comparison, the murine antibody C25 directed
against BoNT/A1-HC was humanized (HuC25) to enable therapeutic use and engineered to enhance
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its cross-reactivity with BoNT/A2. A mutant variant (CR2) was isolated with improved affinity to
BoNT/A2 (from 109 nM to 87 pM), whilst retaining its affinity to BoNT/A1 (115 pM). It was later
shown that the CR2 had the same inhibitory capacity against the enzymatic activity of BoNT/A1 and
BoNT/A2 [52].
The demonstration of the protective synergistic effect during the AntiBotABE project is in good
agreement with previous studies with an oligoclonal recombinant antibody preparation composed
of 3 mAbs directed against BoNT/A [53] and studies on the combination of two mAbs directed
against HC and the -LC domains of BoNT/A [54]. A combination of the four germline-humanized
anti-BoNT/A and B IgGs with a formerly described anti-BoNT/E antibody would result in a promising
oligoclonal antibody product that could be effective against the three main BoNTs serotypes involved
in human botulism cases.
In combination, the germline-humanized IgG targeting the HC and LC domain of BoNT/A and B
are neutralizing in vivo and it is expected that these IgGs are well tolerated in humans with less or no
adverse effect. In contrast to usual therapeutics, such as BabyBIG® or HBAT, they can be produced in
large amount without the use of animals and are suitable for further clinical development as part of an
oligoclonal drug for treatment of botulism. Such a drug would be helpful both for the European Union
biodefense and for the treatment of natural botulism.
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progress have been presented as oral presentations and posters at international meetings by the
Consortium members.
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